NCT01941836View on ClinicalTrials.gov

Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Hypercholesterolemia
Interventions
DRUG

ETC-1002

Patients receive ETC-1002

DRUG

Ezetimibe

Patients receive ezetimibe

Trial Locations (68)

12553

New Windsor

14221

Williamsville

14609

Rochester

23294

Richmond

23502

Norfolk

26900

Beachwood

27408

Greensboro

27609

Raleigh

28144

Salisbury

28401

Wilmington

29464

Mt. Pleasant

30033

Decatur

30066

Marietta

32081

Ponte Vedra

32127

Port Orange

32223

Jacksonville

32765

Oviedo

33012

Hialeah

33409

West Palm Beach

33462

Atlantis

33511

Brandon

33756

St. Petersburg

35209

Birmingham

35662

Muscle Shoals

37660

Kingsport

43213

Columbus

43302

Marion

44094

Willoughby Hills

44124

Lyndhurst

44195

Cleveland

45005

Franklin

45219

Cincinnati

45227

Cincinnati

47714

Evansville

66214

Kansas City

68510

Lincoln

73103

Oklahoma City

74136

Tulsa

75216

Dallas

75230

Dallas

76104

Fort Worth

77030

Houston

77072

Houston

77074

Houston

78681

Round Rock

78731

Austin

80220

Denver

83646

Meridian

84058

Orem

84124

Salt Lake City

85224

Chandler

87106

Albuquerque

90059

Los Angeles

90211

Beverly Hills

90806

Long Beach

91360

Thousand Oaks

91710

Chino

92083

Vista

92663

Newport Beach

95821

Lincoln

97404

Eugene

98057

Renton

98104

Seattle

98502

Olympia

99204

Spokane

06102

Hartford

04210

Auburn

07012

Clifton

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Esperion Therapeutics, Inc.

INDUSTRY